Paraclinical evaluation of side-effects of Taxanes on auditory system;Valutazione degli effetti collaterali dei Taxani sull’apparato uditivo

Acta Otorhinolaryngologica Italica

Volumn 28, Issue 5, 2008, Pages 239-242

  Sarafraz, M ^a   Ahmadi, K ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hearing loss; Ototoxicity; Pure tone audiometery; Side effects; Taxanes

Indexed keywords

TAXOID;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; EAR DISEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; EAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TAXOIDS;

EID: 63049124076     PISSN: 0392100X     EISSN: 1827675X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ligget WH, Forastiere AA. Chemotherapy for head and neck cancer. In: Cummings CW, Haughey BH, Thoma JR, Harker LA, Flint PW, editors. Otolaryngology, head and neck surgery. Fourth edition. Philadelphia: Elsevier Mosby, 2005. p. 108-35.
2. Foland T, Noel J, Cohen L. Vestibular and auditory ototoxicity. In: Cummings CW, Haughey BH, Thoma JR, Harker LA, Flint PW, editors. Otolaryngology, head and neck surgery. Fourth edition. Philadelphia: Elsevier Mosby, 2005. p. 3186-95.
3. Stringer SP, Meyerhoff WL, Wright CG. Ototoxicity. In: Paparella MM, Shumrick DA, Gluckman JL, Meyerhoff WL, editors. Otolaryngology. Third Edition. Philadelphia: W.B.Saunders Company, 1991. p.1653.
4. Kemp DT. Physiologically active cochlear micromechanics: one source of tinnitus. Ciba Found Symp 1981;85:54-81.
5. Rowinsky EK. Antineoplastic, agent (Antimicrotubule agents). In: DeVita VT, Rosenberg SA, Hellman S, editors. Cancer: principles and practice of oncology. Sixth Edition. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2004. p. 431.
6. Haskell CM. Drug therapy. In: Cancer treatment. Fifth edition. Philadelphia, PA, USA: Saunders Company, 2001. p. 2130
7. Lenhard R, Brady L, Osteen R, Gansler T, editors. Clinical oncology. Third edition. Atlanta, Georgia, USA: American Cancer Society, 2001.
8. Paclitaxel USP Drug Information (DI) 2000. Oncology drug information. Third edition. Englewood: Co Micromedix, 1999-2000;339:45.
9. Cortes JE, Pazdur R. Docetaxel. J Clin Oncology 1995;13:2643-55.
10. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neurotoxcity induced by docetaxel. Neurology 1996;46:4-8.
11. Eiseenauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
12. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-8.
13. Norton SJ, Stover LJ. Otoacoustic Emissions: An emerging tool. In: Katz J, editor. Hand book of clinical audiology. Fourth edition. Philladelphia: Lippincot Williams and Wilkins, 1998. p.167
14. Catimel G. A phase II study of gemcytabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:543-7.
15. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-55.
16. Georgoulias V, Ardavanisa A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced nonsmall-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-45.